While Avidity Biosciences Inc has underperformed by -3.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNA rose by 67.74%, with highs and lows ranging from $56.00 to $21.51, whereas the simple moving average jumped by 40.69% in the last 200 days.
On September 17, 2025, Roth Capital started tracking Avidity Biosciences Inc (NASDAQ: RNA) recommending Buy. Bernstein also rated RNA shares as ‘Outperform’, setting a target price of $50 on the company’s shares in an initiating report dated June 24, 2025. Wolfe Research Initiated an Outperform rating on June 17, 2025, and assigned a price target of $55. Raymond James initiated its ‘Strong Buy’ rating for RNA, as published in its report on June 11, 2025. Citigroup’s report from March 13, 2025 suggests a price prediction of $70 for RNA shares, giving the stock a ‘Buy’ rating. BMO Capital Markets also rated the stock as ‘Outperform’.
Analysis of Avidity Biosciences Inc (RNA)
Further, the quarter-over-quarter increase in sales is 88.12%, showing a positive trend in the upcoming months.
One of the most important indicators of Avidity Biosciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -37.76% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.26, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RNA is recording 3.18M average volume. On a monthly basis, the volatility of the stock is set at 5.62%, whereas on a weekly basis, it is put at 5.74%, with a loss of -3.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $68.11, showing growth from the present price of $48.78, which can serve as yet another indication of whether RNA is worth investing in or should be passed over.
How Do You Analyze Avidity Biosciences Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.85%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.03% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
